Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Prospective, Double-Blind, Randomized, Parallel-Group, Dose-Ranging Study of Botulinum Toxin Type A in Men with Glabellar Rhytids

Carruthers, Alastair, MD*; Carruthers, Jean, MD


Background The effective dose for treating glabellar lines with botulinum toxin type A in men has not been studied adequately.

Objective To compare the safety, efficacy, and duration of response of four doses of botulinum toxin type A on glabellar rhytids in men.

Methods Eighty men were randomized to receive a total dose of either 20, 40, 60, or 80 U of botulinum toxin type A (BOTOX, BOTOX Cosmetic, or Vistabel, Allergan, Inc., Irvine, CA, USA) in the glabellar area. Glabellar lines were assessed at rest and maximum frown by a trained observer at baseline, 2 and 4 weeks, and monthly thereafter. Patients provided self-evaluations at the same visits. Adverse events were monitored throughout.

Results The 40, 60, and 80 U doses of botulinum toxin type A were consistently more effective in reducing glabellar lines than the 20 U dose (duration, peak response rate, improvement from baseline). There was a dose-dependent increase in both the response rate at maximum frown and the duration of effect assessed by the trained observer. In addition, the participants reported a dose-dependent reduction in the ability to frown, improvement in their global assessment, and increased feelings of attractiveness, self-confidence, and satisfaction. The incidence of adverse events was not increased with higher doses.

Conclusion Male participants with glabellar rhytids benefit from starting doses of at least 40 U of botulinum toxin type A.

*Department of Dermatology, and Ophthalmology, University of British Columbia, Vancouver, British Columbia, Canada

Address correspondence and reprint requests to: Alastair Carruthers, MD, University of British Columbia, 943 West Broadway, Suite 820, Vancouver, BC V5Z 4E1, or e-mail:

© 2005 by the American Society for Dermatologic Surgery, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website